abstract |
The viability of cancer cells can be reduced by administering an Aurora kinase inhibitor (e.g., MLN8237 or another Aurora A kinase inhibitor, AZD1152 or another Aurora B kinase inhibitor) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 300 kHz (e.g., 200 kHz) to the cancer cells. Furthermore, cancer (e.g., glioblastoma) in a subject may be treated by administering an Aurora kinase inhibitor to the subject, and applying an alternating electric field with frequency between 100 and 300 kHz (e.g., 200 kHz) to a target region of the subject (e.g., the brain). |